Alport Syndrome
Alport syndrome is a hereditary nephropathy caused by mutations in type IV collagen genes, characterized by progressive glomerulonephritis, sensorineural hearing loss, and ocular abnormalities.
Alport Syndrome (Hereditary Nephritis)
Alport syndrome is an inherited disorder of type IV collagen that primarily affects the glomerular basement membrane (GBM), the cochlea, and the eye. The name tells you what it is: "Alport" = after Cecil Alport, the South African physician who first described the association of hereditary nephritis with deafness in 1927; "syndrome" = a constellation of features occurring together.
At its core, this is a basement membrane disease. Type IV collagen is the structural scaffold of basement membranes throughout the body, but the GBM, cochlea (organ of Corti), and lens capsule are particularly dependent on the α3-α4-α5 type IV collagen network — which is precisely what is defective in Alport syndrome [1][2].
Key Concept
Alport syndrome = inherited mutation in type IV collagen genes (COL4A3, COL4A4, or COL4A5) → defective α3-α4-α5 collagen IV network → progressive glomerular disease + sensorineural hearing loss ± ocular abnormalities.
- Prevalence: approximately 1 in 5,000 live births [2]
- Accounts for 0.3–2.3% of new cases of ESRD (end-stage renal disease) [2]
- One of the most common inherited causes of kidney failure — often underdiagnosed because early disease presents only as "asymptomatic haematuria"
- Males with X-linked Alport syndrome are more severely affected; median age of ESRD is 16–35 years for X-linked and autosomal recessive forms [2]
- In Hong Kong and East Asia, Alport syndrome is an important cause of familial haematuria and should always be considered when a young patient (especially male) presents with persistent glomerular haematuria + family history of renal failure or deafness
Since this is a genetic disease, "risk factors" really means genetic risk:
- Family history of renal failure, deafness, or haematuria — the single most important risk factor
- Male sex (for X-linked form): males are hemizygous (only one X chromosome), so a single mutant copy of COL4A5 = full-blown disease
- Specific genotype: truncating mutations (nonsense, frameshift, large deletions) in COL4A5 tend to cause earlier ESRD than missense mutations
- Proteinuria > 1 g/day and hearing loss before age 30 are clinical predictors of faster progression to ESRD
Anatomy & Function: Type IV Collagen and the GBM
The GBM is a specialized extracellular matrix lying between the glomerular endothelium and the podocytes. It has three layers:
- Lamina rara interna (endothelial side)
- Lamina densa (central dense layer — the main filtration barrier)
- Lamina rara externa (podocyte side)
The GBM's structural integrity depends on a network of type IV collagen, which forms a mesh-like scaffold.
Type IV collagen has six α-chains (α1 through α6), encoded by genes COL4A1 through COL4A6. These chains assemble into triple-helix trimers (protomers) that then cross-link into a network:
| Network | Chains | Where found | Role |
|---|---|---|---|
| α1-α1-α2 | COL4A1 + COL4A2 | Ubiquitous (all basement membranes); also the embryonic/fetal GBM | Basic structural scaffold |
| α3-α4-α5 | COL4A3 + COL4A4 + COL4A5 | Mature GBM, cochlear basement membrane, lens capsule, retina | Replaces the embryonic network; provides mechanical strength and resistance to proteolysis |
| α5-α5-α6 | COL4A5 + COL4A6 | Bowman's capsule, skin, smooth muscle | Tissue-specific functions |
Why does Alport syndrome target the kidney, ear, and eye? Because the α3-α4-α5 network is specifically expressed in the GBM, the basement membrane of the cochlea (supporting the organ of Corti), and the lens capsule/retina. Other basement membranes (e.g., skin, gut) use the ubiquitous α1-α1-α2 network and are therefore spared.
The organ of Corti is the sensory organ of hearing, sitting on the basilar membrane in the cochlea. The basement membrane connecting the organ of Corti to the basilar membrane contains the α3-α4-α5 collagen IV network. Defective collagen → ↓ adhesion of the organ of Corti to the basilar membrane → progressive sensorineural hearing loss, beginning in the high-frequency range [1][2].
The lens capsule (the thickest basement membrane in the body) and retinal basement membranes also express α3-α4-α5 collagen IV. Defects here cause anterior lenticonus (forward protrusion of the lens), perimacular retinal flecks, and other ocular pathology.
Aetiology & Genetics
| Pattern | Frequency | Gene(s) | Key Points |
|---|---|---|---|
| X-linked (XL) | ~80% | COL4A5 (Xq22.3) | Most common form. Father-to-son transmission does not occur (father passes Y to son). Males = full-blown disease; females = heterozygous carriers with variable expression [1] |
| Autosomal recessive (AR) | ~15% | COL4A3 or COL4A4 (chromosome 2q36) | Both alleles must be mutated. Males and females equally affected. Similar severity to XL males. |
| Autosomal dominant (AD) | < 5% | Heterozygous COL4A3 or COL4A4 | Associated with slower disease progression (ESRD typically > 45 years). Some develop thin basement membrane disease instead (reason unknown) [2] |
X-linked Inheritance — Key Exam Points
- Father-to-son transmission does not occur in X-linked Alport — because fathers pass the Y chromosome to sons [1].
- An affected father passes the mutant X to all daughters → they become carriers.
- Women with X-linked Alport syndrome are heterozygous carriers. Almost all have some degree of haematuria, and some develop renal failure due to lyonization (random X-inactivation) [1].
- Lyonization = in each cell, one X chromosome is randomly inactivated. If the normal X is preferentially inactivated in a carrier female's kidneys, she may express significant disease.
The type of mutation in COL4A5 predicts severity in X-linked Alport:
- Truncating mutations (nonsense, frameshift, splice-site, large deletions): → complete absence of α5 chain → no α3-α4-α5 network assembled → severe disease, ESRD by ~20 years
- Missense mutations: → structurally abnormal but partially functional α5 chain → milder disease, ESRD at ~30 years or later
- Splice-site mutations: variable severity
Pathophysiology
This is best understood as a stepwise process from gene to disease:
-
Collagen IV malformation: COL4A3-5 encodes the 3 α-chains that form α3-4-5 collagen IV fibres in GBM [2]
-
Glomerular injury: malformation of α3-4-5 network → persistence of embryonic α1-1-2 network [2]
- Why does the embryonic network persist? During normal kidney development, the GBM transitions from the fetal α1-α1-α2 network to the mature α3-α4-α5 network (a process called the "collagen IV switch"). In Alport syndrome, the α3-α4-α5 network cannot be made, so the fetal α1-α1-α2 network persists by default.
-
↑ susceptibility to endoproteolysis and oxidative stress → GBM splitting and damage [2]
- The α1-α1-α2 network lacks the extensive disulfide cross-links that make the α3-α4-α5 network resistant to proteases. It is essentially a "weaker" scaffold.
-
Progressive CKD: GBM damage → secondary glomerulosclerosis (GS) + tubulointerstitial fibrosis (TIF) → proteinuria and progressive CKD [2]
- As the GBM deteriorates, podocytes are injured (foot process effacement), mesangial expansion occurs, and the typical scarring cascade follows.
- Defective α-3-4-5 type IV collagen → ↓ adhesion of the Organ of Corti (the auditory sensory cells) to the basilar membrane → high-tone deafness [1]
- This is a structural problem: the organ of Corti literally loses its mechanical coupling to the basilar membrane, impairing sound transduction starting with high frequencies (because the basal turn of the cochlea, responsible for high frequencies, is most vulnerable).
- Defective α3-α4-α5 collagen in the lens capsule → anterior lenticonus (the lens bulges forward because its capsule is weak)
- Defective collagen in retinal basement membranes → perimacular flecks (dot-and-fleck retinopathy)
Classification
| Type | Gene | Inheritance | Severity |
|---|---|---|---|
| Type 1 (X-linked) | COL4A5 | X-linked | Severe in males; variable in carrier females |
| Type 2 (Autosomal recessive) | COL4A3 or COL4A4 | AR | Severe, similar to XL males |
| Type 3 (Autosomal dominant) | COL4A3 or COL4A4 (heterozygous) | AD | Milder; may overlap with thin basement membrane disease |
- Classic Alport syndrome: haematuria + progressive CKD + sensorineural hearing loss ± ocular features
- Alport syndrome without hearing loss: some patients (especially with milder missense mutations) may not develop hearing loss
- Alport syndrome with leiomyomatosis: rare variant (contiguous gene deletion involving COL4A5 and COL4A6 on Xq22) → diffuse leiomyomatosis of the oesophagus, tracheobronchial tree, and female genital tract
Clinical Features
A. Symptoms (with pathophysiological basis)
| Symptom | Pathophysiological Basis |
|---|---|
| Asymptomatic persistent haematuria, usually in early childhood (< 10 years) [2] | Defective GBM → RBCs leak through the damaged basement membrane. Haematuria is glomerular in origin: smoky/cola-coloured, dysmorphic RBCs, no clots (urokinase in glomerular filtrate lyses clots) [3] |
| Episodic gross (macroscopic) haematuria — often triggered by URTIs | Intercurrent infections cause transient haemodynamic and inflammatory stress on the already-damaged GBM, transiently worsening RBC leakage |
| Later develop proteinuria (< 1–2 g/day) [2] | Progressive podocyte injury secondary to GBM damage → loss of slit-diaphragm integrity → protein leakage. Proteinuria is usually subnephrotic (< 3.5 g/day) |
| Oedema (rare, late) | If proteinuria becomes nephrotic range (uncommon), hypoalbuminaemia → reduced oncotic pressure → oedema |
| Symptoms of CKD (fatigue, nausea, anorexia, pruritus) — late | Progressive CKD: GBM damage → secondary glomerulosclerosis + tubulointerstitial fibrosis → declining GFR → uraemic symptoms [2] |
| Symptom | Pathophysiological Basis |
|---|---|
| Bilateral sensorineural hearing loss, beginning in high-frequency range and progressing to affect lower frequencies [2] | ↓ adhesion of Organ of Corti to basilar membrane via defective α-3-4-5 collagen IV [1][2]. High frequencies are affected first because the basal cochlear turn (high-frequency zone) has the highest mechanical demands |
| Difficulty hearing conversations in noisy environments (early) | High-frequency hearing loss impairs speech discrimination, especially against background noise |
| Not present at birth — develops progressively in late childhood/adolescence | The cochlear basement membrane undergoes cumulative mechanical stress; the fetal α1-α1-α2 network gradually fails under ongoing acoustic vibration |
Key point: Hearing deficit is common → pure-tone audiometry (PTA) is the investigation [1]. In any young patient with haematuria, ALWAYS ask about hearing and arrange PTA.
| Symptom | Pathophysiological Basis |
|---|---|
| Progressive visual deterioration (if anterior lenticonus is present) | Anterior lenticonus = forward bulging of the lens due to weak capsule (defective collagen IV) → irregular refraction → progressive myopia and astigmatism |
| Visual disturbance from retinal flecks (usually asymptomatic) | Perimacular dot-and-fleck retinopathy — deposits in the retina around the macula; usually does not significantly impair vision |
B. Signs (with pathophysiological basis)
| Sign | Pathophysiological Basis |
|---|---|
| Urinalysis: haematuria (microscopic or macroscopic) | GBM defect → glomerular RBC leak |
| Dysmorphic RBCs and RBC casts on urine microscopy | RBCs are distorted as they squeeze through the damaged GBM and conform to tubular shape |
| Hypertension (develops in adolescence/early adulthood) | Progressive glomerulosclerosis → sodium retention + RAAS activation → hypertension |
| Oedema (late) | Significant proteinuria → hypoalbuminaemia |
| Signs of uraemia (late): asterixis, pericardial rub, uraemic frost | End-stage renal failure → accumulation of uraemic toxins |
| Sign | Pathophysiological Basis |
|---|---|
| Sensorineural hearing loss on PTA — initially high-frequency (2000–8000 Hz), later involving lower frequencies [2] | Structural failure of cochlear basement membrane |
| Weber test: lateralizes to the better ear (or midline if bilateral) | Sensorineural loss = inner ear problem → sound not conducted more efficiently via bone |
| Rinne test: air conduction > bone conduction bilaterally (positive Rinne) — but both are reduced | Sensorineural loss preserves the AC > BC relationship but at lower absolute levels |
| Sign | Pathophysiological Basis |
|---|---|
| Anterior lenticonus (pathognomonic for Alport syndrome) [2] | Forward bulging of the central portion of the lens due to thinning and weakness of the anterior lens capsule (defective collagen IV). Seen on slit-lamp exam as an "oil droplet" reflex on retroillumination |
| Perimacular retinal flecks (dot-and-fleck retinopathy) [2] | Yellow-white deposits around the macula on fundoscopy — due to abnormal Bruch's membrane (which also contains type IV collagen) |
| Posterior polymorphous corneal dystrophy [2] | Defective collagen IV in Descemet's membrane (corneal basement membrane) → corneal endothelial vesicular lesions |
| Recurrent corneal erosion [4] | Defective adhesion of corneal epithelium to its basement membrane |
| Sign | Pathophysiological Basis |
|---|---|
| Leiomyomatosis (2–5%) [2] | Contiguous deletion of COL4A5 and COL4A6 → abnormal smooth muscle basement membranes → benign smooth muscle tumours of the oesophagus, tracheobronchial tree, or female genital tract |
| Thoracic/abdominal aortic aneurysms [2] | Rare; defective collagen IV in the vascular basement membrane → structural weakness of the aortic wall |
Clinical Pearl: Anterior Lenticonus
Anterior lenticonus is virtually pathognomonic for Alport syndrome. If you see this on slit-lamp examination in a patient with haematuria, the diagnosis is essentially confirmed. No other common condition causes anterior lenticonus.
Histopathology
- EM shows: thinning (earliest change), splitting of lamina densa (laminated), alternate thinning/thickening (basket-weave appearance) [2]
- The "basket-weave" pattern is the hallmark EM finding: the GBM shows irregular thickening with splitting of the lamina densa into multiple interlacing layers, with electron-dense granular deposits within the splits
Why does the GBM look like a basket-weave? The defective α1-α1-α2 network that persists in place of the normal α3-α4-α5 network is mechanically unstable. Under ongoing filtration pressure, it undergoes cycles of damage, attempted repair, and re-damage → layered splitting and irregular thickening.
- Severity of histologic changes increases with age [2]
- Children may show only thinning of the GBM (may be confused with thin basement membrane disease)
- Adolescents/adults show the classic basket-weave pattern
- Should be negative on standard IF (no immune complex deposition — this is NOT an immune-mediated disease) [2]
- Negative for α3, α4, α5 chain immunostains if special collagen IV chain-specific antibodies are used [2]
- In X-linked Alport males: absent staining for α3, α4, and α5 in GBM (all three chains are needed to form the heterotrimer; if α5 is absent, α3 and α4 cannot be incorporated)
- In carrier females: mosaic pattern (some segments of GBM stain, others do not — reflecting lyonization)
Histology Summary — High Yield for Exams
| Feature | Finding |
|---|---|
| LM | Non-specific early; later GS + TIF + foam cells |
| EM | Basket-weave appearance — alternating thinning and thickening with lamina densa splitting |
| IF | Negative (no immune deposits); absent α3-α4-α5 staining with specific antibodies |
This is a classic exam question [1][4]:
How can the three glomerular causes of haematuria be distinguished? [1]
| Feature | IgA Nephropathy | Alport Syndrome | Thin Basement Membrane Disease (TBMD) |
|---|---|---|---|
| Gross haematuria | Common | Common | Unusual (< 10%) [1] |
| Timing | Synpharyngitic (concurrent with URTI) | Persistent from childhood | Persistent, often detected incidentally |
| Family history | May run in families but no particular mode of inheritance, no one gene [1] | Renal failure / deafness primarily in males, X-linked dominant mode of inheritance [1] | Runs in families [1]; 30–50% have FHx of haematuria; generally benign course [4] |
| Inheritance | Non-Mendelian | X-linked (80%), AR, AD | AD |
| Hearing loss | No | Yes (SNHL) | No |
| Ocular features | No | Yes (anterior lenticonus, retinal flecks) | No |
| Prognosis | Variable (20–40% progress to ESRD over 20 years) | Progressive → ESRD | Benign (usually no CKD) |
| EM | Mesangial deposits | Basket-weave GBM | Thin GBM (diffusely < 250 nm; best visualised by electron microscopy [1]) |
| IF | Mesangial IgA | Negative | Negative |
Key evaluation approach: History + urinalysis of family members [1]
Exam Tip
Do NOT confuse thin basement membrane disease with early Alport syndrome. In young children, the GBM in Alport may be thin (before the basket-weave develops), and this can mimic TBMD on EM. The key differentiators are: (1) family history pattern, (2) hearing loss, (3) genetic testing for COL4A mutations, and (4) serial follow-up — Alport progresses while TBMD does not.
- ESRD usually occurs at 16–35 years old (for X-linked and AR cases) [2]
- AD Alport: ESRD typically > 45 years [2]
High Yield Summary
Alport Syndrome — Key Points for Exams:
- Definition: Inherited type IV collagen disorder (COL4A3/A4/A5) → defective α3-α4-α5 collagen IV network in GBM, cochlea, eye
- Inheritance: X-linked 80% (COL4A5), AR 15% (COL4A3/A4), AD < 5%
- No father-to-son transmission in X-linked form
- Female carriers (X-linked): almost all have haematuria, some develop renal failure (lyonization)
- Pathogenesis: Absent α3-4-5 network → persistence of embryonic α1-1-2 network → susceptible to proteolysis → GBM splitting → basket-weave on EM → GS + TIF → CKD → ESRD
- Clinical triad: Haematuria/CKD + SNHL (high-tone first) + ocular abnormalities (anterior lenticonus = pathognomonic)
- EM: Basket-weave GBM (alternating thinning/thickening, lamina densa splitting)
- IF: Negative (NOT immune-mediated)
- PTA: Investigation of choice for hearing loss
- Distinguished from TBMD: TBMD is AD, benign course, thin GBM, no hearing/eye involvement; Alport progresses to ESRD
- ESRD age: 16–35y (XL males, AR); > 45y (AD)
Active Recall - Alport Syndrome
[1] Senior notes: Block A - Glomerular and Tubulo-interstitial Diseases and Acute Kidney Injury.pdf (p10, Alport syndrome section) [2] Senior notes: Ryan Ho Urogenital.pdf (p60, Section 3.2.3 Alport Syndrome) [3] Senior notes: Maksim Medicine Notes.pdf (p230, Nephrology - haematuria section) [4] Senior notes: Ryan Ho Fundamentals.pdf (p358, Section 3.5.4 Isolated Glomerular Haematuria)
Differential Diagnosis of Alport Syndrome
When a patient presents with the core features of Alport syndrome — persistent glomerular haematuria, sensorineural hearing loss (SNHL), ocular abnormalities, and/or a family history of renal failure — the clinician must systematically consider alternative diagnoses that can mimic one or more of these features. The differential diagnosis should be approached from two angles:
- What else presents as isolated/persistent glomerular haematuria? (the most common initial presentation)
- What else presents as a combined renal + deafness syndrome? (the more specific presentation)
We also need to consider mimics of the progressive CKD component and conditions that share histological features.
This is the classic "three causes of isolated glomerular haematuria" framework, which is extremely high-yield [1][2][4]:
The three classic causes of isolated glomerular haematuria are: (1) IgA nephropathy, (2) Alport syndrome, and (3) thin basement membrane disease (TBMD) [1][4]
| Feature | IgA Nephropathy | Alport Syndrome | Thin Basement Membrane Disease |
|---|---|---|---|
| Age of onset | Usually adult (20–30y) | Childhood (< 10 years) [2] | Childhood (often detected incidentally) |
| Gross haematuria | Common — classically synpharyngitic (concurrent with URTI) [4] | Common — may be triggered by intercurrent illness | Unusual (< 10%) [1] |
| Pattern of haematuria | Episodic macroscopic on background of microscopic | Persistent microscopic with occasional macroscopic | Persistent microscopic; rarely macroscopic |
| Proteinuria | Variable; can become nephrotic | < 1–2 g/day, develops later [2] | Usually minimal (< 0.5 g/day) |
| Family history | Runs in families but no particular mode of inheritance, no one gene [1] | Renal failure / deafness primarily in males, X-linked dominant mode of inheritance [1] | Runs in families — AD; 30–50% FHx of haematuria; generally benign course [4] |
| SNHL | No | Yes — bilateral, high-frequency first | No |
| Ocular features | No | Yes — anterior lenticonus (pathognomonic), retinal flecks | No |
| Prognosis | Variable (20–40% → ESRD over 20y) | Progressive → ESRD (16–35y for XL/AR) | Benign — vast majority never develop CKD |
| EM | Mesangial electron-dense deposits | Basket-weave GBM (splitting of lamina densa) [2] | Thin GBM (diffusely < 250 nm; best visualised by electron microscopy [1]) |
| IF | Mesangial IgA deposits | Negative [2]; absent α3-α4-α5 staining | Negative |
| Serology | Elevated serum IgA in ~50% | No specific serological marker | No specific serological marker |
Key Distinguishing Approach
History + urinalysis of family members is the first-line approach to distinguish these three conditions [1]. Ask about:
- Family history of renal failure and deafness (→ Alport)
- Family history of haematuria without progression (→ TBMD)
- No clear Mendelian pattern (→ IgA nephropathy)
- Hearing assessment (PTA) and slit-lamp examination can clinch Alport syndrome without biopsy
Why TBMD and Alport Overlap — and How to Tell Them Apart
This is a frequent source of confusion. The reason they overlap is genetic: TBMD is caused by heterozygous COL4A3 or COL4A4 mutations — i.e. carriers of the autosomal recessive form of Alport syndrome carry one defective allele, which is enough to thin the GBM and cause haematuria, but not enough to cause the full progressive disease [5].
- Some patients with heterozygous COL4A3/A4 mutations develop thin BM disease instead of Alport syndrome (reason unknown) [2]
- In young children, early Alport syndrome can show GBM thinning only (before the basket-weave develops) — indistinguishable from TBMD on a single biopsy
- Serial follow-up is key: TBMD stays stable; Alport progresses (proteinuria increases, GFR declines, hearing worsens)
Common Exam Mistake
Do NOT diagnose "thin basement membrane disease" from a single paediatric renal biopsy showing thin GBM — this may be early Alport syndrome. Always correlate with family history, PTA, genetic testing, and longitudinal follow-up.
When a patient has both nephropathy and sensorineural hearing loss, the differential narrows significantly:
| Condition | Renal Feature | Hearing Feature | Key Differentiator |
|---|---|---|---|
| Alport syndrome | Progressive GN → ESRD | Bilateral high-frequency SNHL | Basket-weave GBM on EM; COL4A mutation; anterior lenticonus |
| Branchio-oto-renal (BOR) syndrome | Structural renal anomalies (renal agenesis, dysplasia, duplex collecting systems) | Mixed or SNHL + branchial cleft anomalies + preauricular pits/tags | EYA1 gene mutation; structural malformations rather than GN |
| CHARGE syndrome | Variable renal anomalies | SNHL (cochlear malformation) | Coloboma, heart defects, choanal atresia, genital/ear anomalies; CHD7 mutation |
| Distal RTA (Type 1) with SNHL | Nephrocalcinosis, metabolic acidosis, hypokalemia | SNHL | ATP6V1B1 or ATP6V0A4 mutation (encodes H+-ATPase in kidney AND cochlea); acidosis + stones, not haematuria-predominant [7] |
| Mitochondrial diseases (e.g., MELAS, MIDD) | FSGS, tubulopathy | SNHL (often maternal inheritance) | Maternal inheritance; lactic acidosis; diabetes mellitus; myopathy |
| Fabry disease | Proteinuria → CKD; podocyte inclusion bodies (zebra bodies on EM) | SNHL (variable) | X-linked; angiokeratomas, acroparaesthesias, cornea verticillata; α-galactosidase A deficiency |
| Bartter syndrome (neonatal) | Salt-wasting, hypokalaemic metabolic alkalosis, nephrocalcinosis | SNHL (Bartter type IV — BSND mutation) | Polyhydramnios, prematurity; alkalosis not acidosis; no haematuria [8] |
The key differentiator for Alport is the combination of glomerular haematuria (not structural anomalies or tubulopathy) + progressive CKD + high-frequency SNHL + ocular abnormalities (especially anterior lenticonus).
Alport syndrome is one cause of CKD presenting in adolescence/young adulthood. When evaluating a young patient with unexplained CKD:
Causes of CKD (from CKD lecture) [6]:
- Diabetes → 51% of CKD cases in HK [6]
- Hypertension / vascular [6]
- Chronic glomerulonephritis e.g. IgA GN [6]
- Chronic pyelonephritis [6]
- Polycystic kidney disease [6]
- Drug-induced, TIN, TCM [6]
- Myeloma (CRAB), monoclonal gammopathy [6]
- Vasculitis, SLE, other autoimmune diseases [6]
- Obstruction, kidney stones [6]
- Alport's or other hereditary or rare diseases [6]
- Obesity [6]
In a young patient specifically, the likely causes shift:
- IgA nephropathy (most common primary GN worldwide)
- Lupus nephritis (especially young females in Asia)
- Alport syndrome (if FHx of renal failure + deafness)
- FSGS (primary or secondary — including HIV-associated in endemic areas)
- Reflux nephropathy
- ADPKD (if family history + bilateral large cystic kidneys on imaging)
Since renal biopsy is sometimes performed before the clinical picture is clear, it helps to know what other conditions may be confused with Alport on biopsy:
| Histological Finding | Alport Syndrome | Potential Mimics |
|---|---|---|
| Thin GBM (early) | Early Alport (especially in children) | TBMD (most common mimic); early diabetic nephropathy (uniform thickening later, not thinning) |
| Basket-weave GBM splitting (EM) | Classic Alport | Almost pathognomonic — no common mimic |
| Negative IF | Alport (non-immune) | TBMD (also negative); Minimal change disease (but no GBM changes); Pauci-immune crescentic GN (but crescents present) |
| FSGS pattern on LM (late) | Secondary FSGS from progressive Alport | Primary FSGS; HIV-associated FSGS; reflux nephropathy; obesity-related FSGS |
| Foam cells (interstitial) | Characteristic but not pathognomonic | Nephrotic syndrome of any cause (lipid-laden macrophages from heavy proteinuria) |
This is a unique differential relevant to Alport patients who have received a renal transplant [5]:
- May develop de novo anti-GBM disease (3%) after transplantation [5]
- Mechanism: the donor kidney expresses normal α3-α4-α5 collagen IV — which the Alport patient's immune system has never been exposed to → the recipient may form anti-α5 (or anti-α3) antibodies that attack the graft GBM → crescentic GN [5]
- This must be differentiated from transplant rejection (cellular or antibody-mediated) and recurrent disease (not applicable in Alport since the original disease is genetic, not immune)
| Diagnostic Clue | Points Toward | Points Away From |
|---|---|---|
| FHx renal failure + deafness in males | Alport syndrome | TBMD, IgA nephropathy |
| Synpharyngitic haematuria (concurrent URTI) | IgA nephropathy | Alport (haematuria is persistent, not timed to URTI onset) |
| Anterior lenticonus | Alport (pathognomonic) | Everything else |
| Benign course, no proteinuria, no CKD | TBMD | Alport |
| Elevated serum IgA | IgA nephropathy | Alport, TBMD |
| Low C3 | Lupus nephritis, MPGN, PSGN | Alport (complement is normal) |
| Structural renal anomalies | BOR syndrome, CHARGE | Alport (kidneys are structurally normal) |
| Metabolic acidosis + nephrocalcinosis + SNHL | Distal RTA with deafness | Alport |
| Angiokeratomas + acroparaesthesias | Fabry disease | Alport |
| Father-to-son transmission | AR or AD Alport (or non-Alport) | X-linked Alport [1] |
High Yield Summary
Differential Diagnosis of Alport Syndrome — Exam Essentials:
- Three classic causes of isolated glomerular haematuria: IgA nephropathy, Alport syndrome, TBMD — distinguish by FHx pattern, gross haematuria frequency, hearing/eye involvement, and EM findings.
- TBMD vs early Alport: genetically related (heterozygous COL4A3/A4 carriers can present as either); differentiated by longitudinal course, genetic testing, and EM evolution.
- Renal + deafness syndromes: BOR, CHARGE, distal RTA with SNHL, Fabry, mitochondrial diseases, Bartter type IV — each has distinct non-renal features that separate them from Alport.
- Post-transplant: de novo anti-GBM disease in ~3% of Alport recipients (immune system attacks novel α3-α4-α5 collagen in graft).
- Anterior lenticonus is pathognomonic — no other common condition in the DDx causes it.
- Normal complement levels in Alport — if C3 is low, think lupus nephritis, MPGN, or PSGN instead.
- History + urinalysis of family members [1] is the first-line distinguishing approach.
Active Recall - Differential Diagnosis of Alport Syndrome
References
[1] Senior notes: Block A - Glomerular and Tubulo-interstitial Diseases and Acute Kidney Injury.pdf (p10, Alport syndrome section) [2] Senior notes: Ryan Ho Urogenital.pdf (p60, Section 3.2.3 Alport Syndrome) [4] Senior notes: Ryan Ho Fundamentals.pdf (p358, Section 3.5.4 Isolated Glomerular Haematuria) [5] Senior notes: Ryan Ho Urogenital.pdf (p61, Management and TBMD section) [6] Senior notes: Block A - Chronic Kidney Disease and its Complications.pdf (p8, Causes of CKD) [7] Senior notes: Block A - Nephrotology Teaching Clinic RTD.pdf (p25–27, Distal RTA case) [8] Senior notes: Block A - Nephrotology Teaching Clinic RTD.pdf (p27, Bartter Syndrome case)
Diagnostic Criteria, Diagnostic Algorithm & Investigations for Alport Syndrome
Unlike diseases such as SLE (which has formal ACR/EULAR classification criteria) or AKI (which has KDIGO staging), Alport syndrome is diagnosed through a combination of clinical features, family history, histopathology, and genetic testing. There is no universally accepted single-score diagnostic criterion. Instead, the diagnosis is established when a patient meets a sufficient constellation of findings. The 2013 Alport Syndrome Classification Working Group (later refined) proposed a practical framework that integrates clinical, pathological, and genetic data [2][4][9].
Think of it as a convergence of evidence approach — the more lines of evidence you have, the more certain the diagnosis.
Diagnostic Criteria Framework
The most widely used approach (adapted from the Alport Syndrome Classification Working Group / KDIGO guidelines) recognizes the diagnosis when at least one of the following is met:
Molecular genetic testing for COL4A3-5 mutations is now considered the first-line definitive diagnostic test [4][9].
- Identification of a pathogenic or likely pathogenic variant in COL4A3, COL4A4, or COL4A5 confirms the diagnosis
- With modern next-generation sequencing (NGS) panels, detection rate is > 90% in clinically suspected cases
- Genetic testing also determines the inheritance pattern (X-linked vs AR vs AD) and can predict severity (truncating vs missense mutations)
A renal biopsy demonstrating:
The Flinter criteria require at least 3 of the following 4 features in a family:
| # | Criterion | Rationale |
|---|---|---|
| 1 | Positive family history of macro/microscopic haematuria ± CKD progressing to ESRD | Establishes hereditary nature |
| 2 | Electron microscopy showing GBM splitting/lamellation (basket-weave) on renal biopsy | Characteristic histological finding |
| 3 | Progressive high-frequency sensorineural hearing loss (bilateral) | Cochlear basement membrane involvement |
| 4 | Characteristic ocular signs: anterior lenticonus, perimacular retinal flecks, or posterior polymorphous corneal dystrophy | Ocular basement membrane involvement |
- If only 2 criteria are met → "probable Alport syndrome" — genetic testing is essential
- If the individual is a sporadic case (no FHx) → must rely on biopsy + genetics
Current Best Practice — Genetic-First Approach
In 2025 clinical practice, genetic testing has largely superseded renal biopsy as the primary diagnostic modality for suspected Alport syndrome, especially in children. Biopsy is reserved for cases where: (1) genetics are inconclusive, (2) there is significant proteinuria requiring histological characterisation, or (3) there is diagnostic uncertainty about other glomerulopathies.
Investigation Modalities: Detailed Interpretation
| Test | Expected Finding in Alport | Interpretation / Why |
|---|---|---|
| Urine dipstick | Blood positive (1+ to 3+), protein variable (trace to 2+) | Detects haemoglobin/myoglobin — must confirm with microscopy [9][10] |
| Urine microscopy | Dysmorphic RBCs, RBC casts | Dysmorphic RBCs = squeezed through damaged GBM (membrane distortion). RBC casts = RBCs trapped in Tamm-Horsfall protein in tubules, conforming to tubular shape. Diagnostic of glomerular origin [9][10] |
| Urine protein quantification | < 1–2 g/day initially [2]; may increase with disease progression | 24-hour urine protein is the gold standard but cumbersome; urine protein-to-creatinine ratio (uPCR) or urine albumin-to-creatinine ratio (UACR) on spot morning sample is used clinically [10] |
| Urine culture, cytology, AFB | Should be negative | Exclusion of non-glomerular haematuria [4]: UTI, urinary tract TB, urothelial malignancy |
Lecture Point — Urine Protein Quantification
Gold standard is 24-hour urine protein quantification → but very cumbersome. Urine protein-to-creatinine ratio (uPCR) measured on first morning void is the practical alternative. In QMH, uPCR is used instead of UACR [10]. UACR is preferred for diabetic nephropathy screening specifically.
All Hb-positive dipstick should be accompanied by urine microscopy to differentiate haematuria vs pigmenturia [3]
| Test | Expected Finding | Interpretation |
|---|---|---|
| RFT (Na, K, Cl, urea, creatinine, eGFR) | Normal early; progressive rise in creatinine and fall in eGFR with age | Documents degree of renal impairment. When creatinine rises, GFR has already been reduced by at least 50% [11] |
| CBC | Usually normal early; normocytic normochromic anaemia develops with CKD | Anaemia of CKD (↓ erythropoietin from damaged kidneys). Not a primary feature of Alport itself |
| Serum albumin | Normal unless significant proteinuria develops | Low albumin → nephrotic range proteinuria (uncommon in Alport) |
| Serum complement (C3/C4) | Normal | Critical exclusionary test: ↓C3/C4 → lupus nephritis, MPGN, PSGN, cryoglobulinaemia. Normal C3/C4 generally indicates non-immune-complex-mediated GN [4][12] |
| ANA, anti-dsDNA | Negative | Excludes lupus nephritis [4][12] |
| ANCA | Negative | Excludes ANCA-associated vasculitis [4][12] |
| Anti-GBM antibodies | Negative | Excludes Goodpasture disease. Important: these antibodies target the α3 chain of collagen IV — the same chain that is absent in Alport patients (so Alport patients cannot form anti-GBM antibodies against their own GBM, but can after transplant) [4][12] |
| ASLO titre | Negative / not elevated | Excludes post-streptococcal GN [4][12] |
| HBV/HCV serology | Negative (unless concurrent infection) | Excludes viral-associated MPGN [4][12] |
| Serum IgA | Normal | Elevated in ~50% of IgA nephropathy — but not specific |
Key Exam Point: Serology in Alport
Alport syndrome is NOT an immune-mediated disease. All autoimmune serologies (ANA, ANCA, anti-GBM, complement) should be normal. Serological testing is performed to exclude other glomerulonephritides that can mimic Alport's haematuria/proteinuria pattern. If serologies are positive, reconsider the diagnosis.
Hearing deficit common → pure-tone audiometry (PTA) [1]
| Finding | Interpretation |
|---|---|
| Bilateral high-frequency sensorineural hearing loss (2000–8000 Hz initially) | Due to ↓ adhesion of Organ of Corti to basilar membrane via defective α-3-4-5 type IV collagen → high-tone deafness [1][2] |
| Normal PTA in young children | Does not exclude Alport — SNHL develops progressively (typically late childhood/adolescence). Repeat annually |
| Weber lateralises to better ear; Rinne positive bilaterally | Confirms sensorineural (not conductive) loss |
- PTA should be performed on every patient with suspected Alport syndrome AND all first-degree family members during cascade screening
- Pure tone audiometry is the definitive clinical test for the hearing component of Alport syndrome [4]
| Finding | Significance |
|---|---|
| Anterior lenticonus — "oil droplet" reflex on slit-lamp retroillumination | Virtually pathognomonic for Alport syndrome [2][4]. Forward bulging of lens due to weak capsule (defective collagen IV). No other common condition causes this. |
| Perimacular retinal flecks (dot-and-fleck retinopathy) — on fundoscopy | Common in Alport (~60–70% of X-linked males); due to abnormal Bruch's membrane [2] |
| Posterior polymorphous corneal dystrophy — on slit-lamp | Descemet's membrane involvement [2] |
| Recurrent corneal erosion | Defective corneal epithelial basement membrane adhesion [4] |
- Eye findings are not always present at initial presentation (especially in children) but develop with time
- Annual ophthalmological review is recommended
Molecular genetic testing for COL4A3-5 mutations [4]:
| Aspect | Detail |
|---|---|
| Genes tested | COL4A3 (chr 2), COL4A4 (chr 2), COL4A5 (chr X) |
| Method | Next-generation sequencing (NGS) panel covering all exons + intron-exon boundaries; ± MLPA (multiplex ligation-dependent probe amplification) for large deletions/duplications |
| Detection rate | > 90% in clinically suspected cases |
| Result categories | Pathogenic / Likely pathogenic / Variant of uncertain significance (VUS) / Likely benign / Benign |
| If pathogenic variant found | Diagnosis confirmed; determines inheritance pattern; informs prognosis (truncating = severe; missense = milder) |
| If VUS | Cannot confirm or exclude diagnosis — correlate with clinical/histological data; consider functional studies or re-classification over time |
| If negative | Consider deep intronic variants, mosaicism, or alternative diagnosis; renal biopsy may be needed |
Why genetic testing first?
- Non-invasive (blood draw)
- Avoids renal biopsy in children (biopsy carries risk of bleeding, infection, and requires sedation/anaesthesia in young children)
- Provides definitive inheritance pattern for genetic counselling of the family
- Enables cascade screening of family members
Lecture Point — Genetic Testing vs Biopsy
Definitive tests: pure tone audiometry for Alport syndrome; molecular genetic testing for COL4A3-5 mutations in Alport syndrome or TBMD; kidney biopsy: usually reserved for those with significant proteinuria (> 1g/d) or other features of progressive renal diseases [4]
Kidney biopsy is usually reserved for those with significant proteinuria (> 1g/d) or other features [4] of progressive disease, or when genetic testing is inconclusive.
Contraindications to renal biopsy (relevant general principle) [10]:
- Contracted/small kidneys (hard to find; may only yield fibrous tissue)
- Large cysts (cannot stop the bleeding)
- Solitary kidney (no backup if complication occurs)
- Uncontrolled bleeding diathesis, severe uncontrolled hypertension
Biopsy Processing — Three Modalities:
| Modality | Finding in Alport | Interpretation |
|---|---|---|
| Light Microscopy (LM) | Non-specific early; later focal ↑ cellularity, glomerulosclerosis (GS), tubulointerstitial fibrosis (TIF) [2]. May see foam cells (lipid-laden interstitial macrophages) | LM alone cannot diagnose Alport. Foam cells are suggestive but not pathognomonic |
| Electron Microscopy (EM) | Thinning (earliest), splitting of lamina densa (laminated), alternate thinning/thickening = basket-weave appearance [2] | Hallmark finding. In children may show only thinning (mimics TBMD) — severity increases with age. Normal GBM thickness is 300–400 nm; Alport shows irregular areas from < 150 nm to > 500 nm |
| Immunofluorescence (IF) | Should be negative on standard IF; negative for α3, α4, α5 chain immunostains if chain-specific antibodies are used [2] | Standard IF excludes immune-complex GN (IgA, lupus). Chain-specific staining distinguishes Alport from TBMD (TBMD retains normal α3-α4-α5 staining) |
Collagen IV Chain Immunostaining — Pattern Interpretation:
| Genotype | GBM staining | Bowman's capsule / EBM | Skin biopsy (epidermal BM) |
|---|---|---|---|
| XL male (COL4A5 mutation) | Absent α3, α4, α5 | Absent α5 | Absent α5 |
| XL female carrier | Mosaic pattern (some segments +, some –) for α3, α4, α5 | Mosaic α5 | Mosaic α5 |
| AR Alport (COL4A3 or A4 mutation) | Absent α3, α4; α5 may be present in Bowman's capsule | Variable | α5 present (since COL4A5 is normal) |
| TBMD (heterozygous COL4A3/A4) | Normal α3, α4, α5 staining | Normal | Normal |
Why does absence of ONE chain cause absence of ALL three? The α3-α4-α5 network requires all three chains to form the triple helix. If α5 is absent (X-linked), α3 and α4 cannot be incorporated into the GBM and are degraded intracellularly → all three are absent on staining.
Skin Biopsy as a Surrogate
Skin biopsy of the epidermal basement membrane can be used as a less invasive alternative to renal biopsy for collagen IV chain immunostaining, particularly in X-linked Alport. The epidermal BM normally expresses α5 chain — absence on skin biopsy suggests COL4A5 mutation. However, skin biopsy has limitations in AR Alport (where α5 is normal in skin) and cannot provide EM or LM information about the kidneys.
| Modality | Finding | Role |
|---|---|---|
| USG kidneys | Normal size early (10–12 cm); normal parenchymal echogenicity initially. Small kidneys with increased echogenicity + loss of corticomedullary differentiation in advanced CKD [10][6] | Best non-invasive way to assess and visualize kidneys [6]. Excludes obstruction, cysts (ADPKD), structural anomalies. Must confirm kidneys are not shrunken before biopsy |
| Doppler USG | Normal renal vasculature | Excludes renal artery stenosis as cause of hypertension |
- USG is performed before renal biopsy to ensure adequate kidney size and exclude contraindications [10]
- Differential diagnosis of a small kidney on imaging: chronic kidney disease (dysplastic kidney, scarred/shrunken kidney) [6]
- Normal-sized kidneys with high creatinine → worry about acute process (AKI, GN) → may need biopsy [6]
| Test | Purpose |
|---|---|
| Calcium, phosphate, PTH, vitamin D | CKD-mineral bone disease (CKD-MBD) monitoring |
| Fasting glucose, HbA1c, lipid profile | Cardiovascular risk assessment (CKD patients have accelerated atherosclerosis) |
| Iron studies (ferritin, TSAT) | Anaemia of CKD workup |
| Serum/urine protein electrophoresis | Excludes myeloma kidney (relevant in older patients with CKD of unclear aetiology) |
Once a proband is diagnosed, all first-degree relatives should be screened:
| Test | Who | Why |
|---|---|---|
| Urinalysis (dipstick + microscopy) | All first-degree relatives | History + urinalysis of family members [1] — detect haematuria in carriers/affected individuals |
| RFT + BP | All first-degree relatives | Detect early CKD or hypertension |
| PTA | All first-degree relatives | Detect subclinical SNHL |
| Slit-lamp examination | All first-degree relatives | Detect ocular features |
| Genetic testing for the known familial mutation | At-risk relatives (especially in X-linked: all daughters of affected males; all sons/daughters of carrier females) | Definitive carrier identification; guides reproductive counselling |
Important Counselling Point
Should evaluate carefully for any co-existent Alport syndrome before living-related donor transplantation [5]. A family member being considered as a living kidney donor must be genetically tested to confirm they are NOT a carrier — even if they have normal urinalysis. Carrier females (X-linked) often have haematuria but may still have near-normal renal function; however, donating a kidney may accelerate their progression to CKD.
| Stage | Action | Key Test |
|---|---|---|
| 1. Confirm glomerular haematuria | Urine dipstick + microscopy | Dysmorphic RBCs, RBC casts |
| 2. Exclude non-glomerular causes | Urine culture, cytology, AFB; USG kidneys; ± cystoscopy | Negative for UTI, TB, stones, malignancy |
| 3. Exclude other GN | Serology panel (C3/C4, ANA, ANCA, anti-GBM, ASLO, HBV/HCV) | All should be normal in Alport |
| 4. Assess for extrarenal features | PTA + slit-lamp examination | High-frequency SNHL; anterior lenticonus |
| 5. Definitive diagnosis | Genetic testing (COL4A3/A4/A5) ± renal biopsy with EM + chain-specific IF | Pathogenic mutation OR basket-weave GBM + absent α-chain staining |
| 6. Cascade screening | Urinalysis, PTA, genetics for all first-degree relatives | Identify carriers and affected individuals |
High Yield Summary
Diagnosis of Alport Syndrome — Exam Essentials:
- No single diagnostic criterion — diagnosis by convergence of clinical, genetic, and histological evidence
- Flinter criteria (clinical): ≥ 3 of 4: (i) FHx haematuria/ESRD, (ii) basket-weave GBM on EM, (iii) bilateral SNHL, (iv) ocular signs
- Genetic testing = modern gold standard: COL4A3/A4/A5 sequencing; detection rate > 90%; determines inheritance and prognosis
- Renal biopsy reserved for: proteinuria > 1g/day, inconclusive genetics, or diagnostic uncertainty. Must confirm normal kidney size on USG first
- EM hallmark: basket-weave GBM (alternating thinning/thickening, lamina densa splitting)
- IF: negative standard IF; absent α3-α4-α5 on chain-specific staining (XL males); mosaic in carrier females
- PTA: essential — bilateral high-frequency SNHL; arrange for patient AND all family members
- Anterior lenticonus on slit-lamp = virtually pathognomonic
- All autoimmune serologies should be NORMAL — Alport is NOT immune-mediated; serologies are exclusionary
- Cascade screening: urinalysis + PTA + genetics for all first-degree relatives; mandatory before considering living-related kidney donation
Active Recall - Diagnosis of Alport Syndrome
References
[1] Senior notes: Block A - Glomerular and Tubulo-interstitial Diseases and Acute Kidney Injury.pdf (p10, Alport syndrome section) [2] Senior notes: Ryan Ho Urogenital.pdf (p60–61, Section 3.2.3 Alport Syndrome) [3] Senior notes: Maksim Medicine Notes.pdf (p230, Nephrology — haematuria section) [4] Senior notes: Ryan Ho Fundamentals.pdf (p358, Section 3.5.4 Isolated Glomerular Haematuria) [5] Senior notes: Ryan Ho Urogenital.pdf (p61, Management — transplant section) [6] Senior notes: Block A - Chronic Kidney Disease and its Complications.pdf (p8–13, Causes of CKD and kidney sizes) [9] Senior notes: Adrian Lui Pediatrics Notes.pdf (p323, Section 9.2.2 Approach to Isolated Hematuria) [10] Senior notes: Block A - Introduction to Renal Investigations (RFT, urine tests and US kidneys).pdf (p1–5) [11] Senior notes: Block A - Nephrology Interactive Tutorial.pdf (p3, creatinine interpretation) [12] Senior notes: Ryan Ho Urogenital.pdf (p63, Evaluation of nephritic syndrome — serology panel)
Management Algorithm & Treatment Modalities for Alport Syndrome
Before diving into specifics, understand the management philosophy for Alport syndrome:
- There is no cure — Alport syndrome is a genetic structural defect in type IV collagen. You cannot fix the gene (yet).
- No specific treatment exists [2] — management is about slowing progression and managing complications.
- The disease trajectory is predictable: haematuria → proteinuria → hypertension → progressive CKD → ESRD → renal replacement therapy. Our job is to delay each transition for as long as possible.
- The two pillars of management are: (a) RAAS inhibition to reduce proteinuria and slow CKD progression, and (b) renal transplantation when ESRD is reached.
Think of it like a bridge with structural cracks — you can't replace the steel, but you can reduce the traffic load (proteinuria/haemodynamic stress) to slow the collapse.
Treatment Modalities — Detailed Discussion
ACEI/ARB if overt proteinuria (UPCR > 2 mg/mg or proteinuria > 4 mg/m²/h) or male with high-risk mutations or microalbuminuria [2]
Why RAAS inhibition works in Alport syndrome:
The GBM in Alport is structurally defective and under constant haemodynamic stress from glomerular filtration pressure. The renin-angiotensin-aldosterone system (RAAS) contributes to:
- Efferent arteriolar vasoconstriction → increased intraglomerular pressure → accelerated GBM damage
- Podocyte injury via angiotensin II–mediated oxidative stress and TGF-β signalling → fibrosis
- Proteinuria via increased filtration pressure across the damaged GBM
By blocking RAAS:
- ACEI (e.g., ramipril, enalapril): inhibit angiotensin-converting enzyme → less angiotensin II → efferent arteriolar vasodilation → reduced intraglomerular pressure → less proteinuria → slower progression
- ARB (e.g., losartan, valsartan): block angiotensin II type 1 receptors → same downstream effect
| Aspect | Detail |
|---|---|
| Drug class | ACE inhibitor (first-line) or ARB (if ACEI-intolerant, e.g., persistent dry cough) |
| Examples | Ramipril 2.5–10 mg/day; enalapril 5–20 mg/day; losartan 25–100 mg/day |
| Indication | Overt proteinuria (UPCR > 2 mg/mg); or male with high-risk mutation; or microalbuminuria [2] |
| Target | Reduce proteinuria by ≥ 50% or to < 0.5 g/day; BP < 130/80 (adults) or < 90th percentile (children) |
| When to start | Current evidence (EARLY-PRO-TECT trial, 2022) supports starting at the microalbuminuria stage or even pre-emptively in high-risk males (truncating COL4A5 mutations) before overt proteinuria develops |
| Monitoring | Check serum K⁺ and creatinine 1–2 weeks after initiation or any dose change. Acceptable rise in creatinine: up to 20–30% from baseline (reflects haemodynamic effect). If > 30%, suspect other causes (bilateral renal artery stenosis, dehydration) |
Contraindications to ACEI/ARB:
| Absolute | Relative |
|---|---|
| Bilateral renal artery stenosis | Pre-existing hyperkalaemia (K⁺ > 5.5) |
| Pregnancy / women of childbearing age without contraception (teratogenic — renal agenesis, oligohydramnios) | Severe CKD (eGFR < 15) — can still be used cautiously with close monitoring |
| History of angioedema with ACEI (for ACEI specifically; can try ARB cautiously) | Hypotension (SBP < 90) |
| Allergy to the specific drug |
Exam Point: Why NOT combine ACEI + ARB?
Dual RAAS blockade (ACEI + ARB together) was historically tried to maximise proteinuria reduction. However, the ONTARGET and VA NEPHRON-D trials showed that combination therapy increases the risk of hyperkalaemia, AKI, and hypotension without clear benefit in slowing CKD progression. Do not combine ACEI + ARB — use one or the other.
| Aspect | Detail |
|---|---|
| Drug class | Sodium-glucose cotransporter-2 inhibitors |
| Examples | Dapagliflozin 10 mg/day; empagliflozin 10 mg/day |
| Mechanism | Block glucose and sodium reabsorption in proximal tubule → (a) afferent arteriolar vasoconstriction via tubuloglomerular feedback → reduced intraglomerular pressure (complements ACEI/ARB's efferent effect); (b) natriuresis; (c) anti-inflammatory and anti-fibrotic effects |
| Evidence | DAPA-CKD trial (2020) included patients with proteinuric CKD (some with Alport); showed 39% RR reduction in composite kidney endpoint. 2025 KDIGO guidelines recommend SGLT2i for proteinuric CKD regardless of aetiology |
| Indication in Alport | Add-on to ACEI/ARB when proteinuria remains > 0.5 g/day despite maximised RAAS inhibition, AND eGFR ≥ 20 mL/min |
| Contraindications | eGFR < 20 (can continue if already started and eGFR drops below); Type 1 diabetes (risk of DKA); recurrent genital infections |
| Monitoring | eGFR may dip 10–20% on initiation (haemodynamic, similar to ACEI) — acceptable and expected; stabilises after 2–4 weeks |
Control hypertension [6] is a key therapeutic objective in CKD.
- Target: < 130/80 mmHg in adults with proteinuria; < 90th percentile in children
- First-line: ACEI or ARB (as above — dual benefit of BP lowering + renoprotection)
- Add-on if needed: calcium channel blockers (amlodipine), beta-blockers, diuretics (loop or thiazide depending on eGFR)
- Avoid thiazides once eGFR < 30 (ineffective); use loop diuretics (furosemide) instead
- Low-salt diet (< 5 g/day NaCl) potentiates the effect of RAAS inhibitors
| Measure | Rationale |
|---|---|
| Low-salt diet (< 5 g/day NaCl) | Potentiates ACEI/ARB effect; reduces BP and proteinuria |
| Adequate hydration | Maintains renal perfusion; avoids dehydration-induced AKI on top of CKD |
| Avoid nephrotoxins | NSAIDs, aminoglycosides, iodinated contrast — all worsen CKD. Consider and reverse use of any nephrotoxic drugs [13] |
| Exercise | Regular moderate exercise improves cardiovascular fitness (major cause of death in CKD patients is CV disease) |
| Smoking cessation | Smoking accelerates CKD progression and worsens cardiovascular risk |
| Hearing aids | For SNHL — referral to ENT/audiologist when PTA shows functionally significant loss. Does not halt progression but greatly improves quality of life |
| Ophthalmological management | Anterior lenticonus → progressive myopia/astigmatism → may need lens replacement surgery (phacoemulsification + IOL) when visual impairment is significant |
Avoid Nephrotoxins — Practical List
| Drug/Agent | Why Harmful | Alternative |
|---|---|---|
| NSAIDs | Inhibit prostaglandin-mediated afferent arteriolar vasodilation → ↓ GFR → AKI; also can cause interstitial nephritis | Paracetamol for analgesia |
| Aminoglycosides (gentamicin) | Direct proximal tubular toxicity | Use alternative antibiotics; if aminoglycoside essential, monitor drug levels and adjust for eGFR |
| Iodinated contrast | Contrast-induced nephropathy via renal vasoconstriction + direct tubular toxicity | Pre-hydration with IV saline; minimise contrast volume; use low-osmolality contrast; consider MRI (no iodine) |
| TCM / herbal remedies | Unpredictable nephrotoxicity (aristolochic acid nephropathy well-documented in HK) | Avoid entirely |
As Alport syndrome progresses to CKD stages 3–5, the same CKD complications arise as in any CKD of other aetiologies. The management principles are identical:
Therapeutic objectives for CKD: delay kidney failure, control hypertension, reduce albuminuria, treat anaemia and MBD disorder, treat acidosis and high K, control lipid and CV risk [6]
| Complication | Pathophysiology | Management |
|---|---|---|
| Anaemia of CKD | ↓ erythropoietin production by damaged kidneys; iron deficiency from reduced absorption and chronic inflammation | Iron supplementation (IV iron if on dialysis; oral if pre-dialysis); erythropoiesis-stimulating agents (ESA) — epoetin alfa, darbepoetin — target Hb 10–11.5 g/dL (do NOT over-correct → thrombosis risk) |
| CKD-MBD (mineral bone disease) | ↓ phosphate excretion → hyperphosphataemia; ↓ 1,25-dihydroxyvitamin D production → hypocalcaemia; → secondary hyperparathyroidism | Phosphate binders (calcium carbonate with meals, sevelamer, lanthanum); active vitamin D (calcitriol or alfacalcidol); calcimimetics (cinacalcet) for refractory secondary hyperPTH |
| Metabolic acidosis | ↓ ammoniagenesis and ↓ bicarbonate regeneration by damaged tubules | Oral sodium bicarbonate (target serum HCO₃⁻ ≥ 22 mmol/L). Correcting acidosis slows CKD progression, improves muscle wasting, and reduces bone buffering |
| Hyperkalaemia | ↓ K⁺ excretion by damaged distal nephrons; exacerbated by ACEI/ARB | Low-potassium diet; loop diuretics; potassium binders (sodium polystyrene sulphonate / patiromer / sodium zirconium cyclosilicate) |
| Cardiovascular risk | CKD is an independent CV risk factor (accelerated atherosclerosis, vascular calcification) | Statins (atorvastatin); BP control; smoking cessation; glucose control if diabetic; antiplatelet therapy if indicated |
| Fluid overload | ↓ sodium and water excretion | Salt restriction; loop diuretics (furosemide); fluid restriction if severe |
6. Renal Replacement Therapy — When ESRD is Reached
Renal transplant: preferred option over dialysis [2]
| Aspect | Detail |
|---|---|
| Timing | Pre-emptive transplantation (before dialysis is needed) is ideal; typically planned when eGFR < 15–20 mL/min |
| Why preferred over dialysis | Better long-term survival, better quality of life, freedom from dialysis schedule, better cardiovascular outcomes |
| Living vs deceased donor | Living donor transplant has superior graft survival. However, in Alport syndrome, living-related donors must be carefully evaluated (see below) |
| Special considerations | Should evaluate carefully for any co-existent Alport syndrome before living-related donor transplantation [2] |
Why is living-related donor evaluation critical in Alport?
Because the family members of an Alport patient may themselves be:
- Affected (especially in AR Alport — siblings may be homozygous)
- Carriers (in X-linked — all daughters of affected males are carriers; in AR — parents are obligate carriers)
- Carrier females (X-linked) may have haematuria and subclinical disease that would worsen after uninephrectomy
Mandatory workup before accepting a living-related donor:
- Genetic testing for the known familial COL4A mutation
- Urinalysis (haematuria screening)
- PTA (hearing loss screening)
- Full renal function assessment (eGFR, proteinuria quantification)
- If carrier status confirmed → NOT suitable as donor (unless fully counselled about risks and consented in exceptional circumstances)
May develop de novo anti-GBM disease (3%) as some may express anti-α5 or anti-α3 Ab → attack graft kidney GBM → crescentic GN [2]
| Aspect | Detail |
|---|---|
| Mechanism | Alport patient's immune system has never been exposed to normal α3-α4-α5 collagen IV. The transplanted kidney expresses these "new" antigens → recipient forms anti-GBM antibodies (typically anti-α5 or anti-α3) → linear IgG deposition on graft GBM → crescentic GN |
| Frequency | ~3% of transplanted Alport patients [2] |
| Risk factors | Males with X-linked Alport + truncating COL4A5 mutations (complete absence of α5 chain → strongest neoantigen response) |
| Timing | Usually within the first year post-transplant |
| Presentation | Rapid decline in graft function; haematuria; proteinuria; → graft biopsy shows crescentic GN with linear IgG on IF |
| Treatment | Plasmapheresis and cyclophosphamide [2] — same as treatment for native anti-GBM disease |
| Prognosis | Poor — often leads to graft loss despite treatment. If graft is lost, re-transplantation carries high risk of recurrence |
| Modality | Considerations |
|---|---|
| Haemodialysis | Requires AV fistula (ideally created ≥ 6 months before anticipated need); 3 sessions/week. Many Alport patients are young and active — HD significantly impacts lifestyle |
| Peritoneal dialysis | Home-based; preserves residual renal function longer; may suit younger patients for initial RRT; requires intact peritoneal membrane |
Indications for dialysis initiation (same as any CKD → ESRD) — remember the mnemonic AEIOU [13]:
- Acidosis: refractory metabolic acidosis (pH < 7.1)
- Electrolytes: refractory hyperkalaemia (K⁺ > 6.5)
- Intoxication: drug overdose requiring removal (less relevant in Alport)
- Overload: fluid overload refractory to diuretics
- Uraemia: uraemic symptoms (pericarditis, neuropathy, encephalopathy)
| Therapy | Mechanism | Status (2025) |
|---|---|---|
| Bardoxolone methyl | Nrf2 activator → anti-inflammatory, anti-fibrotic effects in the kidney | Phase 3 trials (CARDINAL) showed improvement in eGFR but concerns about heart failure events. Not yet standard of care |
| Gene therapy | Corrective gene replacement or editing (CRISPR-based) for COL4A5 | Preclinical studies; not yet in human trials for Alport |
| Chaperone therapy | Small molecules that stabilise misfolded collagen IV chains (for missense mutations) | Very early experimental stage |
| Anti-miR-21 (lademirsen) | Targets microRNA-21 which promotes fibrosis → reduces tubulointerstitial fibrosis | Phase 2 trials in Alport syndrome showed slowed GFR decline; Phase 3 trials underway |
| Aspect | Detail |
|---|---|
| When | At diagnosis and before any reproductive decisions |
| Key messages | Inheritance pattern (X-linked, AR, AD); recurrence risk for offspring; option of prenatal diagnosis or preimplantation genetic testing (PGT-M) |
| X-linked: affected father | All daughters will be carriers; no sons will be affected (they receive Y) |
| X-linked: carrier mother | 50% chance each son is affected; 50% chance each daughter is a carrier |
| AR: both parents carriers | 25% chance affected; 50% carrier; 25% unaffected |
| Reproductive options | PGT-M with IVF; prenatal testing (amniocentesis/CVS); natural conception with postnatal testing |
| Stage | Key Features | Management Priority |
|---|---|---|
| Haematuria only | Microscopic haematuria, normal RFT, no proteinuria | Annual monitoring; consider pre-emptive ACEI in high-risk males; avoid nephrotoxins; cascade screening |
| Microalbuminuria / proteinuria | uPCR rising; eGFR still normal or mildly reduced | ACEI/ARB — titrate to max dose; add SGLT2i if proteinuria persists; low-salt diet; BP control |
| Established CKD | Declining eGFR; hypertension; proteinuria increasing | Continue ACEI/ARB + SGLT2i; manage CKD complications (anaemia, MBD, acidosis, hyperkalaemia, CV risk); transplant workup |
| ESRD | eGFR < 15; uraemic symptoms | Renal transplant (preferred) [2]; dialysis as bridge or alternative; monitor for de novo anti-GBM disease post-transplant |
| All stages | Extrarenal features | Hearing aids for SNHL; ophthalmological management; genetic counselling |
High Yield Summary
Management of Alport Syndrome — Exam Essentials:
- No specific treatment exists [2] — management is supportive + renoprotective
- ACEI/ARB is the cornerstone: start at microalbuminuria (or pre-emptively in high-risk males); titrate to max tolerated dose; target proteinuria reduction ≥ 50%
- SGLT2 inhibitors are emerging add-on therapy (DAPA-CKD evidence) — add when proteinuria persists despite maximal ACEI/ARB
- Avoid nephrotoxins: NSAIDs, aminoglycosides, iodinated contrast, TCM
- CKD complications: treat anaemia (iron + ESA), CKD-MBD (phosphate binders + vitamin D), acidosis (bicarbonate), hyperkalaemia, CV risk (statins)
- Renal transplant is the preferred RRT over dialysis [2]
- Evaluate family members carefully before living-related donation — genetic testing mandatory to exclude carrier status [2]
- De novo anti-GBM disease occurs in ~3% post-transplant — treat with plasmapheresis and cyclophosphamide [2]
- Hearing aids for SNHL; lens surgery for anterior lenticonus if visually significant
- Genetic counselling is essential — discuss inheritance, recurrence risk, PGT-M options
Active Recall - Management of Alport Syndrome
References
[2] Senior notes: Ryan Ho Urogenital.pdf (p60–61, Section 3.2.3 Alport Syndrome — diagnosis and management) [6] Senior notes: Block A - Chronic Kidney Disease and its Complications.pdf (p8–17, CKD therapy aims) [10] Senior notes: Block A - Introduction to Renal Investigations (RFT, urine tests and US kidneys).pdf (p4–5, urine protein quantification and imaging) [13] Senior notes: Ryan Ho Critical Care.pdf (p26, Immediate approach to AKI and dialysis indications)
Complications of Alport Syndrome
Complications of Alport syndrome can be understood as falling into two broad categories: (1) complications arising directly from the underlying collagen IV defect itself (extrarenal manifestations), and (2) complications arising as consequences of progressive CKD and eventually ESRD — which are the same complications seen in CKD of any aetiology. There is also a unique third category: (3) post-transplant complications specific to Alport syndrome.
Think of it this way: the collagen defect is the "first hit" that damages the GBM, cochlea, and eye directly. Then progressive renal damage from the defective GBM leads to a cascade of CKD complications (the "second hit"). Finally, when the patient reaches ESRD and receives a transplant, the immune system encounters collagen IV for the "first time," generating a unique "third hit."
1. Renal Complications (Direct Disease Progression)
This is the most significant complication and the main cause of morbidity.
| Feature | Detail | Pathophysiological Basis |
|---|---|---|
| Progressive CKD: GBM damage → secondary glomerulosclerosis (GS) + tubulointerstitial fibrosis (TIF) → proteinuria and progressive CKD [2] | ESRD usually occurs at 16–35 years old (for X-linked and AR cases); AD cases typically > 45 years [2] | The defective α1-α1-α2 embryonic GBM is susceptible to endoproteolysis → cycles of damage and attempted repair → glomerulosclerosis. Damaged glomeruli release pro-fibrotic cytokines (TGF-β) → tubulointerstitial fibrosis → nephron loss → CKD → ESRD |
| Rate of progression depends on genotype | Truncating COL4A5 mutations: ESRD by ~20y. Missense mutations: ESRD by ~30y. AD heterozygous: ESRD > 45y | Complete absence of α5 chain (truncating) → no α3-4-5 network at all → faster GBM deterioration than missense mutations where a partially functional network exists |
| Proteinuria increases with age | Starts as microalbuminuria → overt proteinuria (< 1–2 g/day) → can occasionally reach nephrotic range | Progressive podocyte injury from ongoing GBM damage → widening of slit diaphragm gaps → increasing protein leak |
- Develops in adolescence or early adulthood as nephron loss progresses
- Mechanism: progressive glomerulosclerosis → sodium retention + RAAS activation → volume expansion + vasoconstriction → hypertension
- Hypertension itself accelerates CKD progression (vicious cycle): ↑BP → ↑intraglomerular pressure → more GBM damage → more nephron loss → more hypertension
- High blood pressure is listed as a key systemic complication of CKD [6]
- Alport patients with already-compromised renal reserve are highly vulnerable to AKI from:
- Nephrotoxic drugs (NSAIDs, aminoglycosides, iodinated contrast)
- Dehydration (intercurrent illness, vomiting, diarrhoea)
- Urinary tract infections
- Even a "mild" insult that a normal kidney could handle may cause significant AKI in an Alport patient because the remaining nephrons are already maximally compensating
2. CKD-Related Systemic Complications
Once CKD develops (typically CKD stages 3–5), the same complications seen in any cause of CKD emerge. These are well-covered in the CKD lectures [6]:
Six systemic complications of chronic kidney disease: fluid retention, metabolic acidosis, high blood pressure, normochromic normocytic anaemia, secondary hyperparathyroidism, bone disease [6]
| Mechanism | Clinical Features | Why It Matters in Alport |
|---|---|---|
| ↓ Erythropoietin (EPO) production by damaged peritubular interstitial cells in the renal cortex → ↓ RBC production | Normochromic normocytic anaemia [6]: fatigue, pallor, exercise intolerance, dyspnoea on exertion | Alport patients are often young and active — anaemia significantly impairs quality of life. Also, anaemia worsens cardiac workload → contributes to LVH and heart failure over time |
Additional contributing factors:
- Iron deficiency (reduced absorption, chronic inflammation)
- Uraemic toxins suppress erythropoiesis and shorten RBC lifespan
- Chronic inflammation → hepcidin elevation → functional iron deficiency
Secondary hyperparathyroidism + bone disease [6]
| Step | Mechanism |
|---|---|
| 1 | Damaged kidneys cannot excrete phosphate → hyperphosphataemia |
| 2 | Damaged kidneys cannot hydroxylate 25-OH vitamin D to active 1,25-(OH)₂ vitamin D (calcitriol) → ↓ calcitriol |
| 3 | ↓ Calcitriol → ↓ intestinal calcium absorption → hypocalcaemia |
| 4 | Hypocalcaemia + hyperphosphataemia + ↓ calcitriol → all stimulate parathyroid gland → secondary hyperparathyroidism [6] |
| 5 | ↑ PTH → increased bone resorption → renal osteodystrophy (osteitis fibrosa cystica, osteomalacia, adynamic bone disease, mixed) |
| 6 | Hyperphosphataemia + hypercalcaemia (from PTH-driven bone resorption) → vascular calcification → ↑ cardiovascular risk |
- In Alport patients, CKD-MBD is particularly concerning because they reach ESRD at a young age (16–35y) — meaning they accumulate decades of bone and vascular damage if not managed early
- CKD resulting in poor activation of Vit D, so hypocalcemia and hyperphosphatemia → body releases more PTH, secondary hyperPTH [6]
Fluid retention [6]:
- ↓ sodium and water excretion → volume expansion → peripheral oedema, hypertension, pulmonary oedema (if severe)
- Chronic volume overload + hypertension + anaemia → left ventricular hypertrophy (LVH) → eventual heart failure
- CKD is an independent cardiovascular risk factor — patients with CKD have accelerated atherosclerosis
- For young Alport patients reaching ESRD in their 20s–30s, cardiovascular disease becomes a leading cause of mortality if they survive to middle age
Metabolic acidosis [6]:
- Damaged tubules lose ability to generate ammonia (ammoniagenesis) and regenerate bicarbonate
- Results in non-anion gap metabolic acidosis initially (similar to type 4 RTA), progressing to high anion gap metabolic acidosis as GFR falls below ~15–20 mL/min (retention of sulphate, phosphate, and other unmeasured anions)
- Consequences: muscle wasting (catabolism), bone buffering (worsens CKD-MBD), accelerated CKD progression
| Electrolyte | Abnormality | Mechanism | Clinical Significance |
|---|---|---|---|
| Potassium | Hyperkalaemia | ↓ distal tubular K⁺ excretion (especially with ACEI/ARB use) | Potentially life-threatening: cardiac arrhythmias (peaked T waves → widened QRS → VF/asystole). Particularly dangerous because Alport patients are on ACEI/ARB as cornerstone therapy |
| Sodium | Variable (often hyponatraemia in advanced CKD) | Dilutional (water retention exceeds sodium retention) | Oedema, confusion if severe |
| Calcium | Hypocalcaemia | ↓ calcitriol production (see CKD-MBD above) | Tetany, perioral tingling, QT prolongation |
| Phosphate | Hyperphosphataemia | ↓ renal phosphate excretion | Vascular calcification, pruritus, worsens hyperPTH |
At very advanced CKD (eGFR < 10–15):
- Accumulation of uraemic toxins (urea, creatinine, indoxyl sulphate, p-cresyl sulphate, etc.)
- Uraemic syndrome: nausea, vomiting, anorexia, metallic taste, uraemic frost (urea crystals on skin), asterixis, pericarditis (uraemic pericarditis — friction rub), encephalopathy, peripheral neuropathy, platelet dysfunction (uraemic bleeding)
- Uraemic pericarditis is an indication for urgent dialysis
- CKD causes immune dysfunction (impaired neutrophil function, lymphocyte dysfunction, complement dysregulation)
- Uraemia itself is immunosuppressive
- Particularly relevant when patients are on immunosuppression post-transplant (see below)
3. Extrarenal Complications (Direct Collagen IV Defect)
These are not "complications" of CKD per se — they are primary manifestations of the collagen IV defect in non-renal tissues. However, they are clinically managed as complications that impact the patient's overall health:
Cochlea — ↓ adhesion of the Organ of Corti (the auditory sensory cells) to the basilar membrane via the defective alpha-3-4-5 type IV collagen [1][14]
| Feature | Detail |
|---|---|
| Pattern | Bilateral high-frequency SNHL, progressing to involve lower frequencies [2] |
| Onset | Late childhood / adolescence (not present at birth) |
| Progression | Gradual and irreversible — eventually may become severe enough to impair daily communication |
| Impact | Social isolation, academic difficulties in children/adolescents, occupational impairment in adults |
| Management | Hearing aids (amplification devices); cochlear implants in severe cases. The hearing loss is structural (basement membrane defect), not amenable to medical treatment |
| Complication | Mechanism | Clinical Impact |
|---|---|---|
| Anterior lenticonus [2] | Weakness of anterior lens capsule (defective collagen IV) → forward lens bulging | Progressive myopia, irregular astigmatism; eventually may require phacoemulsification + IOL implantation |
| Perimacular retinal flecks [2] | Abnormal Bruch's membrane (collagen IV) → yellow-white deposits around macula | Usually does not significantly impair vision; important as a diagnostic sign |
| Posterior polymorphous corneal dystrophy [2] | Defective Descemet's membrane (collagen IV in corneal basement membrane) → vesicular endothelial lesions | Rarely vision-threatening; may cause mild corneal oedema in severe cases |
| Recurrent corneal erosion [4] | Defective adhesion of corneal epithelium to its basement membrane | Painful episodes of corneal epithelial sloughing; treated with lubricants, bandage contact lenses |
| Cataracts | May develop earlier than general population (lens capsule vulnerability) | Managed with standard cataract surgery when visually significant |
- Leiomyomatosis in 2–5% of Alport patients [2]
- Occurs in a specific genetic subtype: contiguous gene deletion involving both COL4A5 and COL4A6 on Xq22
- Benign smooth muscle tumours develop in:
- Oesophagus → dysphagia, retrosternal pain
- Tracheobronchial tree → cough, stridor (rare)
- Female genital tract (vulva, clitoris, uterus) → pelvic mass, menorrhagia
- Management: surgical excision if symptomatic; surveillance imaging if asymptomatic
- Thoracic/abdominal aortic aneurysms [2] — rare but recognised
- Defective collagen IV in vascular basement membranes → structural weakness of the aortic wall → aneurysmal dilatation
- Risk of rupture or dissection — though much rarer than in Marfan syndrome (which affects fibrillin-1 rather than collagen IV)
4. Post-Transplant Complications (Unique to Alport Syndrome)
May develop de novo anti-GBM disease (3%) as some may express anti-α5 or anti-α3 Ab → attack graft kidney GBM → crescentic GN → plasmapheresis and cyclophosphamide [2]
| Feature | Detail |
|---|---|
| Mechanism | Alport patients have never been exposed to normal α3-α4-α5 collagen IV (their own kidneys never produced it). The transplanted kidney expresses these "neoantigens" → the recipient's immune system recognises them as foreign → forms anti-GBM antibodies (usually anti-α5 or anti-α3) → linear IgG deposition on graft GBM → crescentic GN |
| Frequency | ~3% of transplanted Alport patients [2] |
| Risk factors | X-linked males with truncating COL4A5 mutations (complete absence of α5 = strongest neoantigen stimulus). AR patients with complete absence of α3 or α4 also at risk |
| Timing | Usually within 1st year post-transplant |
| Presentation | Rapid graft dysfunction, haematuria, proteinuria |
| Diagnosis | Graft biopsy: crescentic GN with linear IgG staining on IF + circulating anti-GBM antibodies |
| Treatment | Plasmapheresis (remove circulating anti-GBM antibodies) + cyclophosphamide (halt further antibody production) [2][15] |
| Prognosis | Often leads to graft loss despite treatment. Re-transplantation carries risk of recurrence |
Key Concept: Why Anti-GBM Disease Cannot Occur in Native Alport Kidneys
Anti-GBM disease (Goodpasture disease) targets the NC1 domain of α3 collagen IV in the GBM. In Alport syndrome, the α3-α4-α5 network is absent from the patient's own GBM — the antigen simply does not exist. Therefore, anti-GBM disease cannot develop in native Alport kidneys. It can only occur post-transplant when the donor kidney introduces the "missing" collagen IV chains for the first time.
These are not specific to Alport but apply to all renal transplant recipients:
Long-term complications following kidney transplant [16]:
- Infections — CMV, PJP, BK virus, MTB [16]: due to immunosuppression (tacrolimus, MMF, steroids)
- Malignancy — PTLD (B-cell lymphoma, EBV-related) [16]: EBV-driven lymphoproliferation in immunosuppressed patients
- Cardiovascular disease [16]: accelerated atherosclerosis from immunosuppressive drug effects (dyslipidaemia, diabetes), hypertension, and residual CKD-MBD
- Drug-related side effects [16]: calcineurin inhibitor nephrotoxicity, steroid side effects (cushingoid features, osteoporosis, diabetes), mycophenolate (GI side effects, cytopenias)
- Chronic allograft injury [16]: leading cause of late graft failure — progressive interstitial fibrosis and tubular atrophy from both immune (chronic rejection) and non-immune (calcineurin inhibitor toxicity, hypertension) factors
- Recurrence of primary disease [16]: not applicable in the traditional sense for Alport (it's genetic, not immune), but de novo anti-GBM disease is the Alport-specific equivalent
Often overlooked but critically important in Alport syndrome because patients are young:
| Complication | Context |
|---|---|
| Depression and anxiety | Chronic disease diagnosed in childhood; facing progressive kidney failure, hearing loss, and visual problems during formative years |
| Educational and occupational impact | SNHL impairs academic performance; recurrent medical appointments disrupt schooling; ESRD requiring dialysis limits employment |
| Reproductive concerns | Genetic disease → burden of reproductive decision-making; carrier females face uncertainty about their own disease progression (lyonization) |
| Body image and social isolation | Hearing aids, cushingoid appearance (if on steroids post-transplant), dialysis access (AV fistula), oedema |
| Financial burden | Lifelong medical care, dialysis costs, transplant medications |
| System | Complication | Mechanism |
|---|---|---|
| Renal | Progressive CKD → ESRD | GBM defect → glomerulosclerosis + TIF |
| Renal | Hypertension | Nephron loss → sodium retention + RAAS activation |
| Haematological | Normochromic normocytic anaemia | ↓ EPO production by damaged kidneys |
| Bone/Mineral | Secondary hyperPTH, renal osteodystrophy | ↓ calcitriol + hyperphosphataemia → hypocalcaemia |
| Cardiovascular | LVH, heart failure, accelerated atherosclerosis | Chronic volume overload + HTN + anaemia + dyslipidaemia |
| Metabolic | Acidosis, hyperkalaemia | ↓ tubular H⁺ and K⁺ excretion |
| Auditory | Bilateral high-frequency SNHL | Defective cochlear basement membrane |
| Ocular | Anterior lenticonus, retinal flecks, corneal dystrophy | Defective collagen IV in lens capsule, Bruch's membrane, Descemet's membrane |
| Smooth muscle | Leiomyomatosis (oesophagus, tracheobronchial tree, genital tract) | Contiguous COL4A5 + COL4A6 deletion |
| Vascular | Thoracic/abdominal aortic aneurysms | Defective vascular basement membrane collagen IV |
| Post-transplant | De novo anti-GBM disease (~3%) | Neoantigen (normal α3-α4-α5 collagen) in graft → anti-GBM antibodies |
| Post-transplant | Infections, malignancy, drug toxicity, chronic allograft injury | Immunosuppression-related (general transplant complications) |
| Psychosocial | Depression, educational/occupational impairment, reproductive anxiety | Chronic disease in young patients |
High Yield Summary
Complications of Alport Syndrome — Exam Essentials:
- Progressive CKD → ESRD is the principal complication: GBM defect → glomerulosclerosis + TIF → ESRD by age 16–35 (XL males, AR) or > 45 (AD)
- CKD complications are identical to CKD of any cause: anaemia (↓ EPO), CKD-MBD (secondary hyperPTH), fluid overload, metabolic acidosis, hyperkalaemia, CV disease
- Extrarenal complications are DIRECT collagen IV defects — not secondary to CKD: SNHL (cochlear BM), anterior lenticonus (lens capsule), retinal flecks (Bruch's membrane), leiomyomatosis (COL4A5+A6 deletion), aortic aneurysms
- De novo anti-GBM disease post-transplant (~3%): unique to Alport — recipient immune system attacks normal α3-α4-α5 collagen IV in graft → crescentic GN → treat with plasmapheresis + cyclophosphamide
- Psychosocial burden is major — young patients facing lifelong progressive disease affecting kidneys, hearing, and vision
- Hyperkalaemia risk is compounded by ACEI/ARB use (cornerstone treatment) in the setting of declining renal function — requires careful monitoring
Active Recall - Complications of Alport Syndrome
References
[1] Lecture slides: GC 057. Glomerular and Tubulo-interstitial Diseases and Acute Kidney Injury.pdf (p18, Alport syndrome slide) [2] Senior notes: Ryan Ho Urogenital.pdf (p60–61, Section 3.2.3 Alport Syndrome) [4] Senior notes: Ryan Ho Fundamentals.pdf (p358, Section 3.5.4 Isolated Glomerular Haematuria) [6] Senior notes: Block A - Chronic Kidney Disease and its Complications.pdf (p23, systemic complications of CKD) [14] Senior notes: Block A - Glomerular and Tubulo-interstitial Diseases and Acute Kidney Injury.pdf (p10, Alport syndrome section) [15] Senior notes: Block A – Nephrology Data Interpretation.pdf (p15, Treatment of Goodpasture's syndrome) [16] Senior notes: Block A - Renal Replacement Therapies.pdf (p36–40, Long-term complications of renal transplant)
High Yield Summary
Alport Syndrome — Key Points for Exams:
- Definition: Inherited type IV collagen disorder (COL4A3/A4/A5) → defective α3-α4-α5 collagen IV network in GBM, cochlea, eye
- Inheritance: X-linked 80% (COL4A5), AR 15% (COL4A3/A4), AD < 5%
- No father-to-son transmission in X-linked form
- Female carriers (X-linked): almost all have haematuria, some develop renal failure (lyonization)
- Pathogenesis: Absent α3-4-5 network → persistence of embryonic α1-1-2 network → susceptible to proteolysis → GBM splitting → basket-weave on EM → GS + TIF → CKD → ESRD
- Clinical triad: Haematuria/CKD + SNHL (high-tone first) + ocular abnormalities (anterior lenticonus = pathognomonic)
- EM: Basket-weave GBM (alternating thinning/thickening, lamina densa splitting)
- IF: Negative (NOT immune-mediated)
- PTA: Investigation of choice for hearing loss
- Distinguished from TBMD: TBMD is AD, benign course, thin GBM, no hearing/eye involvement; Alport progresses to ESRD
- ESRD age: 16–35y (XL males, AR); > 45y (AD)
High Yield Summary
Differential Diagnosis of Alport Syndrome — Exam Essentials:
- Three classic causes of isolated glomerular haematuria: IgA nephropathy, Alport syndrome, TBMD — distinguish by FHx pattern, gross haematuria frequency, hearing/eye involvement, and EM findings.
- TBMD vs early Alport: genetically related (heterozygous COL4A3/A4 carriers can present as either); differentiated by longitudinal course, genetic testing, and EM evolution.
- Renal + deafness syndromes: BOR, CHARGE, distal RTA with SNHL, Fabry, mitochondrial diseases, Bartter type IV — each has distinct non-renal features that separate them from Alport.
- Post-transplant: de novo anti-GBM disease in ~3% of Alport recipients (immune system attacks novel α3-α4-α5 collagen in graft).
- Anterior lenticonus is pathognomonic — no other common condition in the DDx causes it.
- Normal complement levels in Alport — if C3 is low, think lupus nephritis, MPGN, or PSGN instead.
- History + urinalysis of family members [1] is the first-line distinguishing approach.
High Yield Summary
Diagnosis of Alport Syndrome — Exam Essentials:
- No single diagnostic criterion — diagnosis by convergence of clinical, genetic, and histological evidence
- Flinter criteria (clinical): ≥ 3 of 4: (i) FHx haematuria/ESRD, (ii) basket-weave GBM on EM, (iii) bilateral SNHL, (iv) ocular signs
- Genetic testing = modern gold standard: COL4A3/A4/A5 sequencing; detection rate > 90%; determines inheritance and prognosis
- Renal biopsy reserved for: proteinuria > 1g/day, inconclusive genetics, or diagnostic uncertainty. Must confirm normal kidney size on USG first
- EM hallmark: basket-weave GBM (alternating thinning/thickening, lamina densa splitting)
- IF: negative standard IF; absent α3-α4-α5 on chain-specific staining (XL males); mosaic in carrier females
- PTA: essential — bilateral high-frequency SNHL; arrange for patient AND all family members
- Anterior lenticonus on slit-lamp = virtually pathognomonic
- All autoimmune serologies should be NORMAL — Alport is NOT immune-mediated; serologies are exclusionary
- Cascade screening: urinalysis + PTA + genetics for all first-degree relatives; mandatory before considering living-related kidney donation
High Yield Summary
Management of Alport Syndrome — Exam Essentials:
- No specific treatment exists [2] — management is supportive + renoprotective
- ACEI/ARB is the cornerstone: start at microalbuminuria (or pre-emptively in high-risk males); titrate to max tolerated dose; target proteinuria reduction ≥ 50%
- SGLT2 inhibitors are emerging add-on therapy (DAPA-CKD evidence) — add when proteinuria persists despite maximal ACEI/ARB
- Avoid nephrotoxins: NSAIDs, aminoglycosides, iodinated contrast, TCM
- CKD complications: treat anaemia (iron + ESA), CKD-MBD (phosphate binders + vitamin D), acidosis (bicarbonate), hyperkalaemia, CV risk (statins)
- Renal transplant is the preferred RRT over dialysis [2]
- Evaluate family members carefully before living-related donation — genetic testing mandatory to exclude carrier status [2]
- De novo anti-GBM disease occurs in ~3% post-transplant — treat with plasmapheresis and cyclophosphamide [2]
- Hearing aids for SNHL; lens surgery for anterior lenticonus if visually significant
- Genetic counselling is essential — discuss inheritance, recurrence risk, PGT-M options
High Yield Summary
Complications of Alport Syndrome — Exam Essentials:
- Progressive CKD → ESRD is the principal complication: GBM defect → glomerulosclerosis + TIF → ESRD by age 16–35 (XL males, AR) or > 45 (AD)
- CKD complications are identical to CKD of any cause: anaemia (↓ EPO), CKD-MBD (secondary hyperPTH), fluid overload, metabolic acidosis, hyperkalaemia, CV disease
- Extrarenal complications are DIRECT collagen IV defects — not secondary to CKD: SNHL (cochlear BM), anterior lenticonus (lens capsule), retinal flecks (Bruch's membrane), leiomyomatosis (COL4A5+A6 deletion), aortic aneurysms
- De novo anti-GBM disease post-transplant (~3%): unique to Alport — recipient immune system attacks normal α3-α4-α5 collagen IV in graft → crescentic GN → treat with plasmapheresis + cyclophosphamide
- Psychosocial burden is major — young patients facing lifelong progressive disease affecting kidneys, hearing, and vision
- Hyperkalaemia risk is compounded by ACEI/ARB use (cornerstone treatment) in the setting of declining renal function — requires careful monitoring
Membranoproliferative Glomerulonephritis
Membranoproliferative glomerulonephritis is a pattern of glomerular injury characterized by mesangial cell proliferation, mesangial matrix expansion, and thickening of the glomerular basement membrane due to subendothelial immune complex deposits or complement dysregulation, resulting in a lobular appearance on light microscopy and a "tram-track" double-contour pattern on silver stain.
Thin Basement Membrane Disease
Thin basement membrane disease is a benign hereditary condition characterized by diffuse thinning of the glomerular basement membrane, typically presenting with persistent microscopic hematuria and a favorable prognosis.